Skip to content
Screener

Nuvation Bio NUVB Research And Development Service Revenue — Deferred Revenue

Similar metrics at other companies

ALN
ALNYResearch Services Obligation — Deferred Revenue
$4M-73.5%
Security National Financial Corporation logo
SNFCAPre Need Merchandise And Service Revenue — Deferred Revenue
$22.18M+13.7%
Novavax logo
NVAXTransition Services — Deferred Revenue
$900K-91.6%
Security National Financial Corporation logo
SNFCAPre Need Merchandise And Services — Deferred Revenue
$22.18M+13.7%
Astec Industries logo
ASTEExtended Warranty Revenue — Deferred Revenue
$1.7M+54.5%
10x Genomics, Inc. logo
TXGProducts and Services, Excluding Grant Revenue — Deferred Revenue
$24.3M+16.3%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.22B+177%
Enterprise value$1.97B+223%
P/S13.1×-42.7×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenue.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646

When a customer pays consideration before the Company provides services, the Company records its obligation as a contract liability representing the transaction price allocated to the remaining performance obligations. The contract liabilities as of June 30, 2026 of $17.0 million consists of $0.3 million of deferred revenue which will be recognize as product revenue and the remaining $16.7 million are expected to be recognized as revenue as research and development services are provided over the next 3 years, with $8.5 million expected to be recognized within one year of the balance sheet date.

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's research and development service revenue — deferred revenue?
Nuvation Bio (NUVB) reported research and development service revenue — deferred revenue of $300K in Q2 2026.
What does research and development service revenue — deferred revenue mean?
This metric measures the portion of revenue generated from research and development services that has been invoiced or collected but not yet recognized as earned under accounting standards. It reflects contractual obligations where the company has received payment for R&D services that are yet to be fully performed or delivered to the client. A significant balance in this account serves as a leading indicator of future revenue recognition and provides insight into the company's current backlog of service-based R&D commitments.

Ask your AI about Nuvation Bio's research and development service revenue — deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude